论文部分内容阅读
目的 研究肝细胞癌ＤＮＡ 倍体类型与放射治疗预后的关系。 方法 ４１ 例肝癌患者，其中男性３７例，女性４ 例，用肝瘤穿刺吸取标本并进行ＤＮＡ 倍体类型分析。 结果 ①二倍体肝癌１７ 例（占４１５ ％） ，异倍体肝癌２４ 例（ 占５８５ ％ ） 。②放射治疗过程中，异倍体肝癌恶化者明显较二倍体肝癌为多（Ｐ＜ ００１） ，其预后亦较二倍体肝癌差（ Ｐ＜ ００１）。③不同倍体类型的表现与肿块大小、肿瘤大体类型、ＡＦＰ水平及癌细胞的分化程度并无显著关系。 结论 肝细胞癌的倍体类型有独立的生物学行为，对估计患者预后有积极意义。
Objective To study the relationship between hepatocellular carcinoma DNA type and prognosis of radiation therapy. Methods Forty-one patients with liver cancer, including 37 males and 4 females, were treated with hepatic tumor puncture and analyzed for DNA ploidy type. Results 1 Diploid hepatocellular carcinoma was 17 cases (41.5%), and aneuploid hepatocellular carcinoma was 24 cases (58.5%). 2 During the course of radiation therapy, the patients with exacerbation of heteroploid liver cancer were significantly more than those with diploid liver cancer (P < 0 01), and their prognosis was also worse than that of diploid liver cancer (P < 0 01). 3 There was no significant relationship between the performance of different ploidy types and tumor size, gross tumor type, AFP level and differentiation of cancer cells. Conclusion The ploidy type of hepatocellular carcinoma has independent biological behavior, which has positive significance for estimating the prognosis of patients.